Lonza has acquired the rights to Nona Biosciences’ transferrin receptor (TfR1) blood-brain barrier (BBB) technology and has expanded its strategic collaboration with the company to develop next-generation BBB delivery technologies. Under the agreement, Lonza will immediately offer the technology to developers of central nervous system (CNS) therapies while continuing to work with Nona on future BBB delivery solutions. The blood-brain barrier protects the brain by preventing ma

Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene. With this approval, Itvisma becomes the first and only gene replacement therapy currently approved for this broad SMA population in the European Union. Itvisma is uniquely designed

Drug developers have a new, optimized option for U.S.-based manufacturing, as AGC Biologics enters a strategic partnership with Pyramid Pharma Services. The collaboration combines AGC Biologics’ expertise in drug substance development and manufacturing with Pyramid’s sterile fill-finish capabilities, creating a differentiated U.S.-based offering and providing developers with a fully integrated supply chain solution. Through this partnership, clients gain access to compre

Roche announced today that the US Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of thyroid eye disease (TED). The filing acceptance is based on results from the two randomised, placebo-controlled global phase III SatraGO studies assessing the safety and efficacy of Enspryng in patients with moderate to severe TED.  The data were presented at the American

Everest Medicines today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL(R) (lerodalcibep), a third-generation PCSK9 inhibitor, for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The on-schedule acceptance underscores the Company's disciplined ex

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL® (lerodalcibep), a third-generation PCSK9 inhibitor,  for subcutaneous use as an adjunct to diet and exercise to red

TLATL Innovation Center ("ATLATL"), a global innovation platform for life science research and development, and Samsung Bioepis Co., Ltd., today announced the launch of the Samsung Bioepis Innovation Prize C-Lab Outside (Innovation Prize), an open innovation initiative designed to identify and support promising early-stage biotech companies across the Asia-Pacific region. Applications for the Innovation Prize will open on June 25, 2026. The program seeks innovati

SK pharmteco today announced the launch of SKyvec™, its proprietary, multimodal viral vector platform. Designed to support gene therapy programs at every stage, from early research through clinical supply and commercial manufacturing, the SKyvec™ platform integrates development capabilities with global manufacturing expertise across North America and Europe to significantly accelerate clinical timelines.  The SKyvec™ platform provides a viral vector developmen

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader, have signed an Memorandum of Understanding and intend to into an agreement to advance their partnership in vaccine innovation and to jointly explore the development of a Vaccine Innovation Centre in Abu Dhabi. The collaboration would strengthen capabilities across AI-enabled vaccine discovery, mRNA research, clinical development and manu

Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participatin